Our top pick for
Building a portfolio
Daré Bioscience, Inc is a biotechnology business based in the US. Daré Bioscience shares (DARE) are listed on the NASDAQ and all prices are listed in US Dollars. Daré Bioscience employs 15 staff and has a market cap (total outstanding shares value) of USD$53.6 million.
|Latest market close||USD$1.34|
|52-week range||USD$0.75 - USD$1.78|
|50-day moving average||USD$1.2597|
|200-day moving average||USD$1.1217|
|Wall St. target price||USD$5.58|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.054|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-15)||-6.94%|
|1 month (2020-12-23)||-6.94%|
|3 months (2020-10-22)||34.00%|
|6 months (2020-07-22)||9.84%|
|1 year (2020-01-22)||-21.18%|
|2 years (2019-01-22)||63.39%|
|3 years (2018-01-22)||2.23|
|5 years (2016-01-22)||2.39|
|Gross profit TTM||USD$-533,334|
|Return on assets TTM||-247.13%|
|Return on equity TTM||-10764.21%|
|Market capitalisation||USD$53.6 million|
TTM: trailing 12 months
There are currently 522,611 Daré Bioscience shares held short by investors – that's known as Daré Bioscience's "short interest". This figure is 51.1% up from 345,861 last month.
There are a few different ways that this level of interest in shorting Daré Bioscience shares can be evaluated.
Daré Bioscience's "short interest ratio" (SIR) is the quantity of Daré Bioscience shares currently shorted divided by the average quantity of Daré Bioscience shares traded daily (recently around 1.5 million). Daré Bioscience's SIR currently stands at 0.36. In other words for every 100,000 Daré Bioscience shares traded daily on the market, roughly 360 shares are currently held short.
However Daré Bioscience's short interest can also be evaluated against the total number of Daré Bioscience shares, or, against the total number of tradable Daré Bioscience shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Daré Bioscience's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Daré Bioscience shares in existence, roughly 10 shares are currently held short) or 0.0144% of the tradable shares (for every 100,000 tradable Daré Bioscience shares, roughly 14 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Daré Bioscience.
Find out more about how you can short Daré Bioscience stock.
We're not expecting Daré Bioscience to pay a dividend over the next 12 months.
Daré Bioscience's shares were split on a 1:10 basis on 20 July 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Daré Bioscience shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Daré Bioscience shares which in turn could have impacted Daré Bioscience's share price.
Over the last 12 months, Daré Bioscience's shares have ranged in value from as little as $0.75 up to $1.78. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Daré Bioscience's is 1.8017. This would suggest that Daré Bioscience's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company intends to develop therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single application that completed Phase 3 clinical trials; Ovaprene, a hormone-free, monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone replacement therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214 injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is based in San Diego, California.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.